Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-22. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
D-Ribose-L-cysteine functions as a cysteine prodrug, delivering cysteine in a chemically protected form that may resist premature oxidation. After cellular uptake, enzymatic cleavage releases free L-cysteine, which can then enter the γ-glutamyl cycle for glutathione synthesis. This mechanism differs from N-acetylcysteine, which relies on de-acetylation and exhibits different absorption and metabolic characteristics. While both compounds ultimately increase cysteine availability, direct comparative data in humans remain limited. D-Ribose-L-cysteine is regulated in the United States as a dietary supplement ingredient, not as a pharmaceutical drug. Products containing D-ribose-L-cysteine are subject to dietary supplement regulations under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which prohibit claims that a product can diagnose, treat, cure, or prevent disease. No pharmaceutical drug approvals or therapeutic indications have been granted for D-ribose-L-cysteine by the U.S. Food and Drug Administration.
PHLPP is a member of the PPM family of phosphatases, which requires magnesium or manganese for their activity and are insensitive to most common phosphatase inhibitors, including [okadaic acid]. PHLPP1 and PHLPP2 have a similar domain structure, which includes a putative Ras association domain, a pleckstrin homology domain, a series of leucine-rich repeats, a PP2C phosphatase domain, and a C-terminal PDZ ligand. PHLPP1 has two splice variants, PHLPP1α and PHLPP1β, of which PHLPP1β is larger by approximately 1.5 kilobase pairs. PHLPP1α, which was the first PHLPP isoform to be characterized, lacks the N-terminal portion of the protein, including the Ras association domain. PHLPP's domain structure influences its ability to dephosphorylate its substrates. A PHLPP construct lacking the PH domain is unable to decrease PKC phosphorylation, while PHLPP lacking the PDZ ligand is unable to decrease Akt phosphorylation.
ADP glucose pyrophosphorylase (AGPase) soluble starch synthase (SS) starch branching enzyme (BE) starch debranching enzyme (DBE) Amylopectin is synthesized by the linkage of α(1→4) glycosidic bonds. The extensive branching of amylopectin (α(1→6) glycosidic bond) is initiated by BE and this is what differentiates amylose from amylopectin. DBE is also needed during this synthesis process to regulate the distribution of these branches. The breakdown of amylopectin has been studied in context with the breakdown of starch in animals and humans. Starch is mostly composed of amylopectin and amylose, but amylopectin has been shown to degrade more easily. The reason is most likely because amylopectin is highly branched and these branches are more available to digestive enzymes. In contrast, amylose tends to form helices and contain hydrogen bonding. The breakdown of starch is dependent on three enzymes, among others:
40. Pain Physician. 2026 Sep;29(6):E751. Comment on "Cervical Erector Spinae Plane Block vs. Epidural Steroid Injection for Cervical Radicular Pain: A Clinical Trial". Sacaklidir GY(1), Sacaklidir R(2). Author information: (1)Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey. (2)Sisli Hamidiye Etfal Training and Research Hospital, Department of Physical Medicine and Rehabilitation, Pain Management Section, Istanbul, Turkey.
Sources: en.wikipedia.org
As filaments grow, the pool of available G-actin molecules is managed by G-actin-binding proteins such as profilin and thymosin β-4. Profilin ensures a supply of available actin-ATP by binding to ADP-bound G-actin and promoting the exchange of ADP for ATP. Profilin's binding to the actin molecule physically blocks its addition to a filament's (−) end, but permits it to join the (+) end. Once the actin-ATP has joined the filament, profilin releases it. As formins promote the nucleation and extension of new actin filaments, they recruit profilin to the area, increasing the local concentration of actin-ATP to boost filament growth. In contrast, thymosin β-4 binds and sequesters actin-ATP, preventing it from joining a microfilament. Once an actin fiber is established, the dynamics of its growth or collapse are influenced by numerous proteins. Existing strands can be interrupted by filament cleaving proteins, such as cofilin and gelsolin. Cofilin binds along two actin-ADP molecules in a filament, forcing a movement that destabilizes the filament and causes it to break. Gelsolin inserts itself between actin molecules in a filament, disrupting the filament. After the filament breaks, gelsolin remains attached to the new (+) end, preventing it from growing, thus forcing its disassembly.
The overall fold of Acutolysin A is composed of a twisted β-sheet core flanked by α-helices, forming the characteristic metzincin architecture. Central to this fold is the conserved “Met-turn”, a methionine-containing structural motif that stabilizes the active-site configuration. The three disulfide bonds in AaH I (Cys117–Cys197, Cys159–Cys181, and Cys157–Cys164) are strategically positioned to maintain this fold under physiological conditions and to resist thermal or proteolytic degradation. These disulfide linkages play a crucial role in preserving the shape of the catalytic cleft, ensuring maximal enzymatic activity even in harsh extracellular environments. At the active site is the HELGHNLGLH metalloproteinase motif, which binds a catalytic zinc ion in a tetrahedral geometry. Three histidine residues coordinate the zinc atom, while the fourth ligand is either a water molecule or hydroxide ion, which acts as the nucleophile in peptide bond hydrolysis. The active-site cleft forms a deep groove that accommodates collagen and laminin fibers, aligning them precisely for cleavage. This structural arrangement explains the exceptional potency of AaH I in degrading basement membranes.
July 28 – August 4: 2018 Senior League Baseball World Series in Easley at Easley Recreation Complex The Pariba Little League (Caribbean) defeated the Naamans Little League (East), 7–2, in the final. July 29 – August 5: 2018 Little League Intermediate (50/70) Baseball World Series in Livermore at Max Baer Park The West Seoul LL (Asia-Pacific) defeated the Livermore/Granada LL (Host), 10–0, in the final. August 12 – 19: 2018 Junior League World Series in Taylor at Heritage Park The Shing-Ming Junior LL (Asia-Pacific) defeated the Lufkin LL (Southwest), 2–0, in the final. August 16 – 26: 2018 Little League World Series in South Williamsport at both the Little League Volunteer Stadium and the Howard J. Lamade Stadium The Honolulu LL (West) defeated the South Seoul LL (Asia-Pacific and Middle East), 3–0, in the final.
Adenylyl-sulfate reductase (glutathione) (EC 1.8.4.9) is an enzyme that catalyzes the chemical reaction AMP + sulfite + glutathione disulfide ⇌ {\displaystyle \rightleftharpoons } adenylyl sulfate + 2 glutathione The 3 substrates of this enzyme are adenosine monophosphate, sulfite, and glutathione disulfide, whereas its two products are adenylyl sulfate and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is AMP,sulfite:glutathione-disulfide oxidoreductase (adenosine-5'-phosphosulfate-forming). Other names in common use include 5'-adenylylsulfate reductase (also used for, internal_xref(ec_num(1,8,99,2))), AMP,sulfite:oxidized-glutathione oxidoreductase, (adenosine-5'-phosphosulfate-forming), and plant-type 5'-adenylylsulfate reductase. In plants, APS is reduced by the plastidic enzyme APS reductase (APR; EC 1.8.4.9) in the presence of physiological concentrations of reduced glutathione (GSH), which acts as an electron donor.
BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate) is a reagent commonly used for the synthesis of amides from carboxylic acids and amines in peptide synthesis. It can be prepared from 1-hydroxybenzotriazole and a chlorophosphonium reagent under basic conditions. This reagent has advantages in peptide synthesis since it avoids side reactions like the dehydration of asparagine or glutamine residues. BOP has used for the synthesis of esters from the carboxylic acids and alcohols. BOP has also been used in the reduction of carboxylic acids to primary alcohols with sodium borohydride (NaBH4). Its use raises safety concerns since the carcinogenic compound HMPA is produced as a stoichiometric by-product. PyBOP, a related phosphonium reagent for amide bond formation PyAOP, a related phosphonium reagent for amide bond formation
Sources: en.wikipedia.org
PT-00114, also known as TCAP-1, is a corticotropin-releasing hormone (CRH) inhibitor which is under development for the treatment of generalized anxiety disorder, major depressive disorder, opioid-related disorders, post-traumatic stress disorder (PTSD), and mood disorders. It is taken by subcutaneous injection. The drug is a synthetic analogue of the teneurin C-terminal associated peptides (TCAP) and is a 41-amino acid peptide. It has been reported to produce anxiolytic-like effects in animals, among other effects. PT-00114 is under development by Protagenic Therapeutics and Charles River Laboratories. As of August 2025, it is in phase 1/2 clinical trials for generalized anxiety disorder, major depressive disorder, opioid-related disorders, and PTSD and is in phase 1 trials for mood disorders. It is or was also under development for the treatment of other anxiety and depressive disorders as well as of impulse control disorders and neurodegenerative disorders, but no recent development has been reported for these indications.
Nycomed, a Swiss drug company which manufactures Actovegin, claims it can be used for circulation and nutrition disturbances, skin grafting, burns, and wound-healing impairment. Actovegin has also been used as a performance enhancer. It has been investigated for use in treatment of polyneuropathy in diabetes, and for stroke. One study found that when tissues suffer from hypoxia caused circulation abnormalities, Actovegin helps capillaries improve circulation by enhancing the neogenic mechanism in blood vessels. Anaphylactic shock has been observed in at least one patient treated with actovegin. There are reports suggesting that Actovegin have ergogenic ability, however one small trial found no apparent benefit from short-term use. Two studies certified Actovegin to have an anti-inflammatory effect. One of the two studies certified Actovegin to reduce Progressive muscular atrophy-induced inflammation in human cells. Another study certified Actovegin to have a positive impact on the growth of muscle cells.
Assessment — This step involves collecting data pertinent to the patient, including nutrition-related History, anthropometric Measurements, biochemical data, nutrition-focused physical findings, client history and comparative standards. Diagnosis — Based on the assessment data collected, a nutrition problem may be diagnosed. Causes and contributing factors are identified. Intervention — Based on the nutrition diagnosis, problems are addressed that aid in alleviation of the diagnosis’ signs and symptoms. Activities are constructed to enable the patient to work towards objectives set for them by themselves and their nutrition professional. Monitoring/Evaluation — Progress made on goals and/or expected outcomes is tracked to ensure that nutrition problems are being addressed; adjustments in the Intervention step are made according to progress.
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection (injection under the skin). It works by inactivating tumor necrosis factor (TNF). Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, new onset or exacerbation of demyelinating diseases (such as multiple sclerosis), heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe. Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization's List of Essential Medicines. It is available as a biosimilar medication. In 2023, it was the 244th most commonly prescribed medication in the United States, with more than 3 million prescriptions.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.